[68Ga]Ga-CDI首次人体研究:一种用于肿瘤细胞死亡成像的正电子放射性药物
在5例至少有一个颅外实体恶性肿瘤病灶(>2 cm)且研究前8周内未接受积极抗癌治疗的患者中,给予205 ± 4.1 MBq(范围200-211 MBq)的[68Ga]Ga-CDI并进行8次连续PET扫描(首次立即开始,末次3小时后)。结果显示该药物安全且耐受良好,无副作用或不良事件,经肾脏排泄,平均有效剂量为2.17E-02 ± 4.61E-03 mSv/MBq,可对肿瘤细胞死亡成像且与组织学TUNEL染色相关。
要点
- [68Ga]Ga-CDI安全且耐受良好,无副作用或不良事件。
- 平均有效剂量为2.17E-02 ± 4.61E-03 mSv/MBq。
- 可对肿瘤细胞死亡成像,并与组织学TUNEL染色相关。
核心结论
- [68Ga]Ga-CDI是一种安全、辐射剂量低、生物分布和成像特性优异的新型细胞死亡成像放射性药物,相比既往研究的细胞死亡成像放射性药物具有潜在优势,并已进入概念验证试验。
研究设计与样本
- 首次人体研究,纳入5例至少有一个颅外实体恶性肿瘤病灶>2 cm且研究前8周内未接受积极抗癌治疗的患者。
- 参与者接受205 ± 4.1 MBq(范围200-211 MBq)的[68Ga]Ga-CDI,并进行8次连续PET扫描,首次立即开始,末次3小时后。
- 监测临床、实验室和心电图副作用及不良事件,测量尿液和血液放射性,在肿瘤、血池和器官上绘制球形感兴趣体积以确定生物分布并计算剂量学。
- 对1例参与者的肿瘤标本使用末端脱氧核苷酸转移酶dUTP缺口末端标记(TUNEL)染色分析细胞死亡。
主要发现
- [68Ga]Ga-CDI安全且耐受良好,无副作用或不良事件。
- [68Ga]Ga-CDI经肾脏排泄,在其他器官中显示低水平生理性摄取,具有优异的成像特性。
- 平均有效剂量为2.17E-02 ± 4.61E-03 mSv/MBq。
- 可对肿瘤细胞死亡成像,并与组织学TUNEL染色的肿瘤细胞死亡相关。
局限性
- 试验注册为回顾性注册(ACTRN12621000641897,2021年5月28日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study assesses human biodistribution, radiation dosimetry, safety and tumour uptake of cell death indicator labelled with 68Ga ([68Ga]Ga-CDI), a novel radiopharmaceutical that can image multiple forms of cell death. METHODS: Five participants with at least one extracranial site of solid malignancy > 2 cm and no active cancer treatment in the 8 weeks prior to the study were enrolled. Participants were administered 205 ± 4.1 MBq (range, 200-211 MBq) of [68Ga]Ga-CDI and 8 serial PET scans acquired: the first commencing immediately and the last 3 h later. Participants were monitored for clinical, laboratory and electrocardiographic side effects and adverse events. Urine and blood radioactivity was measured. Spherical volumes of interest were drawn over tumour, blood pool and organs to determine biodistribution and calculate dosimetry. In one participant, tumour specimens were analysed for cell death using terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining. RESULTS: [68Ga]Ga-CDI is safe and well-tolerated with no side effects or adverse events. [68Ga]Ga-CDI is renally excreted, demonstrates low levels of physiologic uptake in the other organs and has excellent imaging characteristics. The mean effective dose was 2.17E - 02 ± 4.61E - 03 mSv/MBq. It images constitutive tumour cell death and correlates with tumour cell death on histology. CONCLUSION: [68Ga]Ga-CDI is a novel cell death imaging radiopharmaceutical that is safe, has low radiation dosimetry and excellent biodistribution and imaging characteristics. It has potential advantages over previously investigated radiopharmaceuticals for imaging of cell death and has progressed to a proof-of-concept trial. TRIAL REGISTRATION: ACTRN12621000641897 (28/5/2021, retrospectively registered).
引用
- Ho Shon I, Hennessy T, Guille J, et al. A first-in-human study of [68Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death. Eur J Nucl Med Mol Imaging. 2022. PMID: 35779082. doi:10.1007/s00259-022-05880-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。